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empirical treatmentInvasive candidiasis (IC) in intensive care units (ICUs) is the
most common cause of fungal infection, and it is associated with a
high attributable mortality.1 [7_TD$DIFF]Many risk factors are associated with
IC and were integrated in different clinical scores (Candida score,
colonization index, Dupont score) but their variable predictive
values, far better for the negative predictive value than for the
positive one, do not allow use as decision tools for treatment
administration.2 Moreover, the absence of effective diagnostic
tools2 spurs us to recommend and largely prescribe empirical
systemic antifungal therapies (SAT) to the ICU patients with risk
factors.3–5 Empirical SAT is associated with increase in costs6 and a
selection of resistant strains,7 and it contributes to the increase in
antifungal consumption responsible for modiﬁcation in fungal
species distribution and susceptibility.8 However, secondarily
proven invasive candidiasis (SPIC) is only observed in a fraction of
those patients who receive an empirical SAT. The objective of this* Corresponding author. Universite´ Paris Diderot/Hoˆpital Bichat - Re´animation
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).studywas to deﬁne the risk factors predictive for SPIC onset during
empirical SAT, by accounting for center and patient variables in a
large prospective cohort.
The subpopulation of non-transplant non-neutropenic adult
ICU patients with an empirical SAT during their ICU stay ( 48 h
post-admission) from a French multicenter prospective observa-
tional study: the AmarCAND2 cohort,1 was included. Patients with
primarily documented invasive candidiasis, deﬁned either with a
positive direct examination or a positive culture and a subsequent
Candida species identiﬁcation at the time of SAT initiation, were
excluded. Patients without primary PIC, i.e., for whom only a
suspicion of IC led to the initiation of SAT, were included and
clustered into two groups according to SPIC onset or not. More
details on the reason for initiation of SAT in patients with
suspected IC were provided in the article by Leroy et al.1 Univariate
analyses were performed to select variables with a p-value
threshold of about 0.25. Selected variables were introduced into
multivariate hierarchical models to identify factors independently
associated with SPIC. The ﬁnal model with the smallest Akaike
information criterionwas chosen. Risk factors that were tested and
not retained in the ﬁnal models were: (1) baseline characteristics:ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Comparaison of the center and patient characteristics according to the presence of secondarily proven invasive candidiasis
Descriptive statistics (N(%))
Absence of secondary PIC
N=432
Secondary PIC
N=112
P-value
Center characteristics
University hospital 322 (74.5) 93 (83) 0.06
ICU type <.01
Medicine 64 (14.8) 19 (17)
Surgery 97 (22.5) 40 (35.7)
Polyvalent 271 (62.7) 53 (47.3)
Hematology unit in the hospital 385 (89.1) 91 (81.3) 0.02
Infectious disease unit in the hospital 313 (72.5) 96 (85.7) <.01
Oncology unit in the hospital 360 (83.3) 93 (83) 0.94
Infectious disease adviser in the ICU** 405 (93.8) 107 (95.5) 0.47
Local protocol for antifungal administration 236 (54.6) 56 (50) 0.38
Local protocol for antibacterial administration 319 (73.8) 79 (70.5) 0.48
Detection of Candida colonization 280 (64.8) 64 (57.1) 0.13
Patient characteristics on ICU admission
Age (median [IQR]) 63.8 [53.2; 73] 63.1 [54.5; 72.3] 0.72
Sex (Male) 268 (62) 69 (61.6) 0.93
Previous duration of hospitalization stay (days, median [IQR]) 2 [0; 10] 1 [0; 7] 0.57
SAPSII score 48 [36; 62] 48 [38; 61] 0.98
Diabetes mellitus 82 (19) 15 (13.4) 0.17
Immunodepression 74 (17.1) 16 (14.3) 0.47
Malignant disease 115 (26.6) 40 (35.7) 0.06
Other comorbidity* 236 (54.6) 58 (51.8) 0.59
Type of ICU admission <.01
Intra-abdominal surgery 189 (43.8) 74 (66.1)
Other surgery 51 (11.8) 12 (10.7)
Medicine 192 (44.4) 26 (23.2)
Patient characteristics on SAT initiation
Previous duration of ICU stay (days, median [IQR]) 4 [1; 12] 1 [0; 8] <.01
Candida scorey [3_TD$DIFF] 3 [2; 3] 2.5 [1; 3] 0.20
SOFA score 8 [5; 11] 7 [5; 10] 0.05
Septic shock 268 (62) 62 (55.4) 0.20
Invasive mechanical ventilation 366 (84.7) 92 (82.1) 0.50
Central venous catheter 417 (96.5) 109 (97.3) 0.68
Urinary catheterization 408 (94.4) 108 (96.4) 0.40
Hemodialysis or hemodiaﬁltration 131 (30.3) 29 (25.9) 0.36
Total parenteral nutrition 185 (42.8) 50 (44.6) 0.73
Antibacterial therapy 384 (88.9) 97 (86.6) 0.97
Corticosteroid treatment 124 (28.7) 27 (24.1) 0.33
Multifocal Candida spp colonizationz [4_TD$DIFF] 116 (26.9) 26 (23.2) 0.43
Red blood cell transfusion 232 (53.7) 57 (50.9) 0.60
Platelet transfusion 94 (21.8) 25 (22.3) 0.90
C-reactive protein (mg/L) 152 [83.2; 234] 173 [102; 255] 0.23
Creatinine (mmol/L) 104.5 [65; 168] 99.5 [56; 176] 0.55
Procalcitonine (ng/L) 2320 [400; 10000] 3640 [360; 11490] 0.54
OR >1 in favor of secondary candidemia.; IQR: interquartile range.
* Other comorbidities: myocardial infarction, congestive heart failure, peripheral venous disease, stroke, dementia, chronic obstructive pulmonary disease, peptic ulcer
disease, mild or severe chronic kidney disease, hemiplegia, mild or severe chronic liver disease.
** i.e. At least one ICU attending physician is also graduated in infectious diseases.
y Candida score was computed on the basis of available data (severe sepsis, surgery admission, parenteral nutrition and the knowledge of multifocal colonization.
z Multifocal Candida spp colonization corresponded to one of the possible reasons for initiating a treatment in a patient with suspected IC.
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than diabetes, immunosuppression, hemopathy and cancer), SAPS
II score; (2) at SAT initiation: invasivemechanical ventilation, SOFA
score, previous length of ICU stay, previous length of hospital stay,
broad spectrum antibacterial therapy in the past ten days,
corticosteroid therapy, total parenteral nutrition, red blood cell
and platelet transfusion, procalcitonin, creatinine, reactive
C-protein, and multifocal Candida spp. colonization. Two sub-
group analyses were performed by considering the type of ICU
admission (intra-abdominal surgery vs. other). A non-parsimoni-
ous p value of <0.10 was retained for analyses. Statistical analyses
were performed by using SAS v9.4 (SAS Institute Inc., Cary, NC,
USA.).
A total of 544 patients were included in the analysis, including
112 (21%) patients with SPIC (candidaemia: 19 (17%), intra-
abdominal IC: 64 (57%) and deep-seated IC: 29 (26%), mainly from
sterile biopsy (N = 17 – 59%)). Secondary PIC were more frequentlyobserved in centers with an infectious disease unit, and the
proportion of SPIC was larger in surgery ICUs compared to medical
ICUs. At ICU admission, the rate of SPIC was higher for patients
admitted for an intra-abdominal surgery (28%) compared to those
admitted for another reason (other surgery or medicine: 14%)
(p <0.01); there was no other signiﬁcant difference between both
groups (Table 1). At SAT initiation, the duration of ICU stay was
shorter for patients with SPIC; otherwise, there were no signiﬁcant
differences between both groups. The rawmortalitywas 26% in the
SPIC group and 33% in the rest of the sample, but the differencewas
not signiﬁcant (Chi square p-value = 0.11). The multivariate
analysis conﬁrmed that patients admitted to the ICU for intra-
abdominal surgery were more than three times as likely to
experience an SPIC as the patients admitted for a medical reason.
Septic shock at SAT initiation decreased the probability for SPIC.
Wemay speculate that the attending physiciansmore often started
antifungal drugs in case of septic shock, leading to a more frequent
Table 2
Result of the multivariate hierarchical model for secondary candidiasis
Secondary candidiasis
N (%)
Variables selected at the last step of the multivariate analysis
No Yes OR [95% CI] P value
All patients
N=544
432 (79) 112 (21) Type of ICU admission <.01
Intra-abdominal surgery 3.06 [1.69; 5.54]
Other surgery 1.88 [0.79; 4.48]
Medicine ref
Septic shock 0.62 [0.38; 1.03] 0.06
Malignant hemopathy and cancer 1.59 [0.95; 2.63] 0.08
Patients with intra-abdominal
surgery (N=263)
[5_TD$DIFF]189 (72) 74 (28) Septic shock 0.53 [0.28; 0.98] 0.04
Malignant hemopathy and cancer 1.70 [0.92; 3.12] 0.09
Patients without intra-abdominal
surgery (N= [6_TD$DIFF]281)
243 (86) 38 (14) No factor associated with PIC
OR>1 in favor of a secondarily documented invasive candidiasis.
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tested and showed no signiﬁcant association with SPIC (Table 2).
Whenwe considered only those patientswhowere admitted to the
ICU for an intra-abdominal surgery, we found an inverse
association between septic shock and ﬁnal diagnosis of SPIC.
When we consider the sub-group of patients who were not
admitted for an intra-abdominal surgery, no risk factor was found
to be associated with SPIC (Table 2). The hierarchical model
conﬁrmed the signiﬁcant variability of the rate of SPIC between
centers, not explained by ﬁxed center-effect variables unmasked in
previous studies (see Table E1 ESM).3
To conclude, the ﬁrst observationwas that in a large prospective
cohort of patients who receive an empirical SAT, only 21%
experienced a documented invasive candidiasis. Intra-abdominal
surgery was identiﬁed as the main and sole risk factor allowing
differentiation of patients with empirical SAT at risk for SPIC.
Conversely, other conventional risk factors such as total parenteral
nutrition, severe sepsis, and previous antibacterial therapy, which
are part of usual clinical scores,2 were unable to identify patients at
risk for SPIC. However, the absence of data on multifocal Candida
colonization, or on biological markers, was a study limitation.
Considering that empirical SAT of non-transplant non-neutropenic
patients has not demonstrated its efﬁciency,9,10 and that usual risk
factors are clearly not sufﬁcient to optimize adequacy of empirical
antifungal therapy, new biomarkers or new diagnostic tests are
urgently needed.
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